Welcome to our dedicated page for Syra Health SEC filings (Ticker: SYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Syra Health’s regulatory disclosures can feel like piecing together a public-health puzzle. The company juggles population health analytics, digital therapeutics such as the Syrenity app, and contract-driven workforce programs—each layer adding complexity to every 10-K risk factor and 8-K update. Investors searching "Syra Health SEC filings explained simply" or "Syra Health insider trading Form 4 transactions" often spend hours locating the numbers that matter.
Stock Titan’s AI bridges that gap in seconds. When a new "Syra Health quarterly earnings report 10-Q filing" hits EDGAR, our engine produces instant summaries, highlights reimbursement footnotes, and sends "Syra Health Form 4 insider transactions real-time" alerts. Need a "Syra Health annual report 10-K simplified" overview, a "Syra Health proxy statement executive compensation" digest, or a "Syra Health 8-K material events explained" snapshot? You’ll get them while the documents are still syncing, complete with red-line changes and expert context.
Practical use cases span monitoring "Syra Health executive stock transactions Form 4" before material announcements to comparing quarter-over-quarter margins via our "Syra Health earnings report filing analysis" dashboards. Every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A, Form 4—is archived, searchable, and paired with AI-powered highlights that surface segment KPIs, population-health metrics, and digital-health adoption rates without wading through 200 pages. Understand Syra Health SEC documents with AI, make faster decisions, and stay ahead of every disclosure.
Syra Health Corp. reported the results of its Annual Meeting of Stockholders. A total of 15,848,410 shares were represented, including 600,000 shares of Class B common stock with 16.5 votes per share.
All five director nominees were elected. Stockholders ratified M&K CPAs, PLLC as independent auditor for the year ended December 31, 2025 with 14,955,596 For, 369,733 Against, and 523,081 Abstain.
Two charter amendments affecting Class B voting structure were approved: (1) deletion of the provision that automatically converts Class B common stock upon the death of a Class B stockholder; and (2) expansion of permitted transfers so that immediate family members, heirs, successors, and assigns may receive Class B shares without those shares converting.
Syra Health (SYRA) filed its Q3 2025 10‑Q, showing a smaller loss alongside a shift in revenue mix and a going concern warning. For the nine months ended September 30, 2025, net revenues were $5,491,944 versus $5,975,357 a year ago, as Healthcare Workforce declined and Population Health grew. Gross profit was $1,896,592 with a gross margin near 35%, up from roughly 22% last year, driven by mix toward higher‑margin project work.
Operating loss was $768,663 and net loss was $761,763, improving from $3,254,841 last year. Cash and cash equivalents were $1,976,545 as of September 30, 2025, with working capital of $2,156,762. The company disclosed substantial doubt about its ability to continue as a going concern and may need additional capital. Customer concentration remained high; Indiana FSSA accounted for approximately 37% of year‑to‑date revenue.
Corporate updates noted an April 11, 2025 voluntary delisting from Nasdaq to OTC QB and leadership changes in June, including appointment of an interim CEO. Class A shares outstanding were 11,339,169 as of November 11, 2025.
Syra Health Corp. filed an 8-K announcing it furnished its third-quarter 2025 results press release. The company reported that a press release covering the quarter ended September 30, 2025 is attached as Exhibit 99.1.
The company stated the information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into other filings unless specifically referenced. The exhibit also includes forward-looking statements subject to cautionary language.
Syra Health Corp proxy excerpts show board composition, director changes, equity holdings and compensation details. The company has an insider trading policy for employees, officers, directors, consultants and related parties. Several directors and executives appear in compensation tables showing 2023 and 2024 total compensation in the low hundreds of thousands, with amounts such as $319,629, $200,730 and $171,291 reported for specific individuals. The disclosure lists equity awards and outstanding option counts for directors and significant holders, and notes audit-related fees of $17,000 and total fees of $92,000 and $114,755. The filing also records personnel changes: Sandeep Allam was reported deceased on January 15, 2025, Andrew Dahlem resigned the board on April 25, 2025, and Deepika Vuppalanchi resigned on July 28, 2025. The company states it does not have a written policy governing timing of option grants around material nonpublic information.
FAQ
What is the current stock price of Syra Health (SYRA)?
What is the market cap of Syra Health (SYRA)?
